Radionuclide therapy of adrenal tumors
Identifieur interne : 001D99 ( Main/Exploration ); précédent : 001D98; suivant : 001E00Radionuclide therapy of adrenal tumors
Auteurs : Jorge A. Carrasquillo [États-Unis] ; Neeta Pandit-Taskar [États-Unis] ; Clara C. Chen [États-Unis]Source :
- Journal of Surgical Oncology [ 0022-4790 ] ; 2012-10-01.
English descriptors
- Teeft :
- Activity mibg, Adrenal, Adrenal tumors, Analog, Biol, Cancer biother radiopharm, Carcinoid, Carrasquillo, Chemotherapy, Clin, Clin oncol, Clinical results, Conventional therapy, Cumulative dose, Cumulative doses, Dos, Dose escalation, Dosimetry, Dotatate, Dotatoc, Endocrinol, Hematologic toxicity, High doses, Higher doses, Hoefnagel, Imaging, Infusion, Large doses, Malignant, Malignant pheochromocytoma, Matthay, Median, Median survival, Metaiodobenzylguanidine, Metaiodobenzylguanidine therapy, Metastatic, Metastatic pheochromocytoma, Mibg, Mibg therapy, Myeloablative chemotherapy, Neuroblastoma, Neuroendocrine, Neuroendocrine tumors, Nucl, Nucl biol, Objective response rate, Objective responses, Oncol, Oncology, Paraganglioma, Partial response, Pediatr, Pediatr blood cancer, Pediatr oncol, Pheo, Pheo patients, Pheochromocytoma, Platelet, Radiolabeled, Radiolabeled metaiodobenzylguanidine, Radionuclide, Radionuclide therapy, Receptor, Refractory, Refractory neuroblastoma, Renal, Renal toxicity, Response rate, Response rates, Retrospective, Retrospective review, Shapiro, Single doses, Sisson, Somatostatin, Stable disease, Surgical, Surgical oncology, Therapeutic doses, Therapy, Toxicity, Tumor size, Whole body, Whole body doses.
Abstract
Adrenal tumors arising from chromaffin cells will often accumulate radiolabeled metaiodobenzylguanidine (MIBG) and thus are amenable to therapy with I‐131 MIBG. More recently, therapy studies have targeted the somatostatin receptors using Lu‐177 or Y‐90 radiolabeled somatostatin analogs. Because pheochromocytoma (PHEO)/paraganglioma (PGL) and neuroblastoma (NB), which often arise from the adrenals, express these receptors, clinical trials have been performed with these reagents. We will review the experience using radionuclide therapy for targeting PHEO/PGL and NBs. J. Surg. Oncol. 2012; 106:632–642. © 2012 Wiley Periodicals, Inc.
Url:
DOI: 10.1002/jso.23196
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001451
- to stream Istex, to step Curation: 001434
- to stream Istex, to step Checkpoint: 000388
- to stream Main, to step Merge: 001E18
- to stream Main, to step Curation: 001D99
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Radionuclide therapy of adrenal tumors</title><author><name sortKey="Carrasquillo, Jorge A" sort="Carrasquillo, Jorge A" uniqKey="Carrasquillo J" first="Jorge A." last="Carrasquillo">Jorge A. Carrasquillo</name></author><author><name sortKey="Pandit Askar, Neeta" sort="Pandit Askar, Neeta" uniqKey="Pandit Askar N" first="Neeta" last="Pandit-Taskar">Neeta Pandit-Taskar</name></author><author><name sortKey="Chen, Clara C" sort="Chen, Clara C" uniqKey="Chen C" first="Clara C." last="Chen">Clara C. Chen</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5802A1239202F735766A9670258296C90FA39223</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1002/jso.23196</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-S8BDB216-T/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001451</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001451</idno><idno type="wicri:Area/Istex/Curation">001434</idno><idno type="wicri:Area/Istex/Checkpoint">000388</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000388</idno><idno type="wicri:doubleKey">0022-4790:2012:Carrasquillo J:radionuclide:therapy:of</idno><idno type="wicri:Area/Main/Merge">001E18</idno><idno type="wicri:Area/Main/Curation">001D99</idno><idno type="wicri:Area/Main/Exploration">001D99</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Radionuclide therapy of adrenal tumors<ref type="note" target="#fn1"></ref></title><author><name sortKey="Carrasquillo, Jorge A" sort="Carrasquillo, Jorge A" uniqKey="Carrasquillo J" first="Jorge A." last="Carrasquillo">Jorge A. Carrasquillo</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Molecular Imaging and Therapy Service, Radiology Department Memorial Sloan Kettering and Radiology Department, Weill Cornell Medical Center, New York</wicri:cityArea></affiliation><affiliation></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Correspondence address: Attending Physician, 1275 York Avenue, New York</wicri:cityArea></affiliation></author><author><name sortKey="Pandit Askar, Neeta" sort="Pandit Askar, Neeta" uniqKey="Pandit Askar N" first="Neeta" last="Pandit-Taskar">Neeta Pandit-Taskar</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Molecular Imaging and Therapy Service, Radiology Department Memorial Sloan Kettering and Radiology Department, Weill Cornell Medical Center, New York</wicri:cityArea></affiliation></author><author><name sortKey="Chen, Clara C" sort="Chen, Clara C" uniqKey="Chen C" first="Clara C." last="Chen">Clara C. Chen</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Division of Nuclear Medicine, Department of Radiology & Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Surgical Oncology</title><title level="j" type="sub">Seminars in Surgical Oncology: Adrenal</title><title level="j" type="alt">JOURNAL OF SURGICAL ONCOLOGY</title><idno type="ISSN">0022-4790</idno><idno type="eISSN">1096-9098</idno><imprint><biblScope unit="vol">106</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="632">632</biblScope><biblScope unit="page" to="642">642</biblScope><biblScope unit="page-count">11</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2012-10-01">2012-10-01</date></imprint><idno type="ISSN">0022-4790</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-4790</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Activity mibg</term><term>Adrenal</term><term>Adrenal tumors</term><term>Analog</term><term>Biol</term><term>Cancer biother radiopharm</term><term>Carcinoid</term><term>Carrasquillo</term><term>Chemotherapy</term><term>Clin</term><term>Clin oncol</term><term>Clinical results</term><term>Conventional therapy</term><term>Cumulative dose</term><term>Cumulative doses</term><term>Dos</term><term>Dose escalation</term><term>Dosimetry</term><term>Dotatate</term><term>Dotatoc</term><term>Endocrinol</term><term>Hematologic toxicity</term><term>High doses</term><term>Higher doses</term><term>Hoefnagel</term><term>Imaging</term><term>Infusion</term><term>Large doses</term><term>Malignant</term><term>Malignant pheochromocytoma</term><term>Matthay</term><term>Median</term><term>Median survival</term><term>Metaiodobenzylguanidine</term><term>Metaiodobenzylguanidine therapy</term><term>Metastatic</term><term>Metastatic pheochromocytoma</term><term>Mibg</term><term>Mibg therapy</term><term>Myeloablative chemotherapy</term><term>Neuroblastoma</term><term>Neuroendocrine</term><term>Neuroendocrine tumors</term><term>Nucl</term><term>Nucl biol</term><term>Objective response rate</term><term>Objective responses</term><term>Oncol</term><term>Oncology</term><term>Paraganglioma</term><term>Partial response</term><term>Pediatr</term><term>Pediatr blood cancer</term><term>Pediatr oncol</term><term>Pheo</term><term>Pheo patients</term><term>Pheochromocytoma</term><term>Platelet</term><term>Radiolabeled</term><term>Radiolabeled metaiodobenzylguanidine</term><term>Radionuclide</term><term>Radionuclide therapy</term><term>Receptor</term><term>Refractory</term><term>Refractory neuroblastoma</term><term>Renal</term><term>Renal toxicity</term><term>Response rate</term><term>Response rates</term><term>Retrospective</term><term>Retrospective review</term><term>Shapiro</term><term>Single doses</term><term>Sisson</term><term>Somatostatin</term><term>Stable disease</term><term>Surgical</term><term>Surgical oncology</term><term>Therapeutic doses</term><term>Therapy</term><term>Toxicity</term><term>Tumor size</term><term>Whole body</term><term>Whole body doses</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Adrenal tumors arising from chromaffin cells will often accumulate radiolabeled metaiodobenzylguanidine (MIBG) and thus are amenable to therapy with I‐131 MIBG. More recently, therapy studies have targeted the somatostatin receptors using Lu‐177 or Y‐90 radiolabeled somatostatin analogs. Because pheochromocytoma (PHEO)/paraganglioma (PGL) and neuroblastoma (NB), which often arise from the adrenals, express these receptors, clinical trials have been performed with these reagents. We will review the experience using radionuclide therapy for targeting PHEO/PGL and NBs. J. Surg. Oncol. 2012; 106:632–642. © 2012 Wiley Periodicals, Inc.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Carrasquillo, Jorge A" sort="Carrasquillo, Jorge A" uniqKey="Carrasquillo J" first="Jorge A." last="Carrasquillo">Jorge A. Carrasquillo</name></region><name sortKey="Carrasquillo, Jorge A" sort="Carrasquillo, Jorge A" uniqKey="Carrasquillo J" first="Jorge A." last="Carrasquillo">Jorge A. Carrasquillo</name><name sortKey="Chen, Clara C" sort="Chen, Clara C" uniqKey="Chen C" first="Clara C." last="Chen">Clara C. Chen</name><name sortKey="Pandit Askar, Neeta" sort="Pandit Askar, Neeta" uniqKey="Pandit Askar N" first="Neeta" last="Pandit-Taskar">Neeta Pandit-Taskar</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Lorraine/explor/InforLorV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D99 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001D99 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Lorraine
|area= InforLorV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:5802A1239202F735766A9670258296C90FA39223
|texte= Radionuclide therapy of adrenal tumors
}}
| This area was generated with Dilib version V0.6.33. |  |